Sight Sciences, Inc.
Sight Sciences, Inc. (Nasdaq: SGHT) develops and sells interventional ophthalmic technologies for glaucoma and dry eye disease, primarily to eye care professionals, including ophthalmic surgeons, optometrists and ophthalmology practices. Its Interventional Glaucoma segment offers the OMNI Surgical System, which… From the company’s description.
Over the twelve months to Sep 30, 2026, Sight Sciences, Inc. reported revenue of $88.39M, up 16.2% from a year earlier, and a net loss of $28.40M. Its operating margin was −29.5%, and operations used $16.92M in cash. In fiscal 2025, it reported revenue of $77.36M, down 3.1% from fiscal 2024, and a net loss of $38.43M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sight Sciences, Inc. does
In the company’s own words
Sight Sciences, Inc. (Nasdaq: SGHT) develops and sells interventional ophthalmic technologies for glaucoma and dry eye disease, primarily to eye care professionals, including ophthalmic surgeons, optometrists and ophthalmology practices. Its Interventional Glaucoma segment offers the OMNI Surgical System, which enables minimally invasive glaucoma surgery to reduce intraocular pressure in adults with primary open-angle glaucoma, and the SION Surgical Instrument, used to remove trabecular meshwork tissue. Its Interventional Dry Eye segment sells the TearCare system, which applies localized heat to treat meibomian gland dysfunction associated with evaporative dry eye, alongside manual gland expression. OMNI and SION are sold mainly to ambulatory surgery centers and hospital outpatient departments; TearCare is sold to optometry and ophthalmology practices. The company has direct commercial operations in the United States, United Kingdom and Germany, and sells OMNI through distributors in other European countries. Its commercial team comprised more than 100 professionals as of December 31, 2025. Its website is www.sightsciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MENLO PARK, CA
- Fiscal year end
- December
- CIK
- 1531177
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sight Sciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sight Sciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sight Sciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sight Sciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sight Sciences, Inc.'s last four quarterly filings that the numbers alone won't show?”